Is this the end of costly and harmful pharmaceutical advertising?

Direct-to-consumer pharmaceutical advertising is under increasing political pressure, with bipartisan legislation being introduced to ban or restrict the practice, and states considering bills to deny tax deductions for pharmaceutical advertising expenses.

This report comes from The Hill. The story centres on Is this the end of costly and harmful pharmaceutical advertising?. Full coverage and background context is available at the original source. Readers seeking more detail on this developing topic are encouraged to follow updates from The Hill and related outlets covering this beat.